{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:00:54Z","timestamp":1784707254410,"version":"3.55.0"},"posted":{"date-parts":[[2026,3,8]]},"group-title":"In Review","reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,25]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Tuberculous meningitis (TB meningitis) is a major cause of death and neurological deficit despite recommended antibiotic and corticosteroid treatments, primarily due to dysregulated neuroinflammation. Here, we investigate a diverse panel of 12 immunomodulatory drugs as host-directed treatments (HDTs) for TB meningitis utilizing a cross-species framework comprising studies in a mouse model of TB meningitis with clinical endpoints, and parallel mechanistic studies in a newly developed immune-vascularized human brain organoid model of TB meningitis and peripheral blood mononuclear cells (PBMCs) from patients with TB meningitis. We identify new HDTs that outperform the current standard of care by reducing mortality and neurological deficits in mice via suppression of neuroinflammation. Importantly, these HDTs significantly reduce microglial activation in\n                  <italic>Mycobacterium tuberculosis<\/italic>\n                  -infected human brain organoids and attenuate proinflammatory cytokines, particularly IFN\u03b3 within CD4\u2009+\u2009T-cells in patient-derived PBMCs. These findings highlight the potential of targeted HDTs to improve outcomes in TB meningitis and warrant clinical investigation.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8694483\/v1","type":"posted-content","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:13:12Z","timestamp":1772989992000},"source":"Crossref","is-referenced-by-count":0,"title":["Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7070","authenticated-orcid":false,"given":"Sanjay","family":"Jain","sequence":"first","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ruiz","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Singh","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuderleys Masias","family":"Leon","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-7759","authenticated-orcid":false,"given":"Xueyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Sarhan","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9568-8998","authenticated-orcid":false,"given":"Yazmin","family":"Martinez-Martinez","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Patel","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelynn","family":"Shambles","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Villabona-Rueda","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadia","family":"Lissit","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[{"name":"National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scerba","sequence":"additional","affiliation":[{"name":"National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-4118","authenticated-orcid":false,"given":"William","family":"Bishai","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Artemov","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-9029","authenticated-orcid":false,"given":"Jinchong","family":"Xu","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"D\u2019Alessio","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hafner","sequence":"additional","affiliation":[{"name":"National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Greig","sequence":"additional","affiliation":[{"name":"NIA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Manion","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-0224","authenticated-orcid":false,"given":"Irini","family":"Sereti","sequence":"additional","affiliation":[{"name":"NIAID"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global tuberculosis report 2025 (2025) World Health Organization"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e0000069","DOI":"10.1371\/journal.pgph.0000069","article-title":"The global burden of tuberculous meningitis in adults: A modelling study","volume":"1","author":"Dodd PJ","year":"2021","unstructured":"Dodd PJ et al (2021) The global burden of tuberculous meningitis in adults: A modelling study. PLOS Glob Public Health 1:e0000069","journal-title":"PLOS Glob Public Health"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"ofaa257","DOI":"10.1093\/ofid\/ofaa257","article-title":"Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis","volume":"7","author":"Stadelman AM","year":"2020","unstructured":"Stadelman AM et al (2020) Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. Open Forum Infect Dis 7:ofaa257","journal-title":"Open Forum Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s00415-019-09523-6","article-title":"Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis","volume":"266","author":"Wen L","year":"2019","unstructured":"Wen L et al (2019) Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis. J Neurol 266:3009\u20133021","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12890-019-0966-8","article-title":"Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis","volume":"19","author":"Wang MG","year":"2019","unstructured":"Wang MG et al (2019) Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis. BMC Pulm Med 19:200","journal-title":"BMC Pulm Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson RJ","year":"2017","unstructured":"Wilkinson RJ et al (2017) Tuberculous meningitis. Nat Rev Neurol 13:581\u2013598","journal-title":"Nat Rev Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","article-title":"Tuberculous meningitis: a roadmap for advancing basic and translational research","volume":"19","author":"Jain SK","year":"2018","unstructured":"Jain SK et al (2018) Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat Immunol 19:521\u2013525","journal-title":"Nat Immunol"},{"key":"ref8","article-title":"A clinical practice guideline for tuberculous meningitis","author":"Donovan J","year":"2025","unstructured":"Donovan J et al (2025) A clinical practice guideline for tuberculous meningitis. Lancet Infect Dis","journal-title":"Lancet Infect Dis"},{"key":"ref9","first-page":"13","article-title":"The treatment of tuberculous meningitis with cortisone and streptomycin","volume":"67","author":"Shane SJ","year":"1952","unstructured":"Shane SJ, Clowater RA, Riley C (1952) The treatment of tuberculous meningitis with cortisone and streptomycin. Can Med Assoc J 67:13\u201315","journal-title":"Can Med Assoc J"},{"key":"ref10","first-page":"CD002244","article-title":"Corticosteroids for managing tuberculous meningitis","volume":"4","author":"Prasad K","year":"2016","unstructured":"Prasad K, Singh MB, Ryan H (2016) Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 4:CD002244","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMoa2216218","article-title":"Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults","volume":"389","author":"Donovan J","year":"2023","unstructured":"Donovan J et al (2023) Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults. N Engl J Med 389:1357\u20131367","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami R","year":"2013","unstructured":"Ruslami R et al (2013) Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27\u201335","journal-title":"Lancet Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/cid\/ciac208","article-title":"Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial","volume":"75","author":"Paradkar MS","year":"2022","unstructured":"Paradkar MS et al (2022) Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial. Clin Infect Dis 75:1594\u20131601","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cell.2011.12.023","article-title":"Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections","volume":"148","author":"Tobin DM","year":"2012","unstructured":"Tobin DM et al (2012) Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148:434\u2013446","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/infdis\/jix050","article-title":"Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis","volume":"215","author":"Thuong NTT","year":"2017","unstructured":"Thuong NTT et al (2017) Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis. J Infect Dis 215:1020\u20131028","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMoa2502866","article-title":"Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis","volume":"393","author":"Meya DB","year":"2025","unstructured":"Meya DB et al (2025) Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. N Engl J Med 393:2434\u20132446","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04138-z","article-title":"Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial","author":"Donovan J","year":"2026","unstructured":"Donovan J et al (2026) Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial. Nat Med","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"100604","DOI":"10.1016\/j.lansea.2025.100604","article-title":"A randomised trial to assess the efficacy of add on therapy with aspirin or clopidogrel to the standard medical therapy alone in patients with tubercular meningitis: ACT TBM","volume":"37","author":"Bhatia R","year":"2025","unstructured":"Bhatia R et al (2025) A randomised trial to assess the efficacy of add on therapy with aspirin or clopidogrel to the standard medical therapy alone in patients with tubercular meningitis: ACT TBM. Lancet Reg Health Southeast Asia 37:100604","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/cid\/ciad401","article-title":"Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study","volume":"77","author":"Manesh A","year":"2023","unstructured":"Manesh A et al (2023) Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis 77:1460\u20131467","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/cid\/ciaa1826","article-title":"Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort","volume":"72","author":"Toorn R","year":"2021","unstructured":"van Toorn R, Solomons RS, Seddon JA, Schoeman JF (2021) Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis 72:e136\u2013e145","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.tube.2021.102125","article-title":"The use of thalidomide to treat children with tuberculosis meningitis: A review","volume":"130","author":"Toorn R","year":"2021","unstructured":"van Toorn R et al (2021) The use of thalidomide to treat children with tuberculosis meningitis: A review. Tuberculosis (Edinb) 130:102125","journal-title":"Tuberculosis (Edinb)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/156652409787581655","article-title":"Pathogenesis of central nervous system tuberculosis","volume":"9","author":"Be NA","year":"2009","unstructured":"Be NA, Kim KS, Bishai WR, Jain SK (2009) Pathogenesis of central nervous system tuberculosis. Curr Mol Med 9:94\u201399","journal-title":"Curr Mol Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1326859","DOI":"10.3389\/fimmu.2024.1326859","article-title":"Interactions between CNS and immune cells in tuberculous meningitis","volume":"15","author":"Ma Q","year":"2024","unstructured":"Ma Q et al (2024) Interactions between CNS and immune cells in tuberculous meningitis. Front Immunol 15:1326859","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/cid\/ciu641","article-title":"Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome","volume":"59","author":"Marais S","year":"2014","unstructured":"Marais S et al (2014) Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 59:1638\u20131647","journal-title":"Clin Infect Dis"},{"key":"ref25","article-title":"High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis","volume":"132","author":"Ruiz-Bedoya CA","year":"2022","unstructured":"Ruiz-Bedoya CA et al (2022) High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J Clin Invest 132","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota F","year":"2022","unstructured":"Mota F et al (2022) Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat Commun 13:7974","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1038\/s41467-024-50989-4","article-title":"Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs","volume":"15","author":"Chen X","year":"2024","unstructured":"Chen X et al (2024) Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs. Nat Commun 15:6657","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12879-018-3633-4","article-title":"Mortality in hospitalized patients with tuberculous meningitis","volume":"19","author":"Soria J","year":"2019","unstructured":"Soria J et al (2019) Mortality in hospitalized patients with tuberculous meningitis. BMC Infect Dis 19:9","journal-title":"BMC Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.19-0098","article-title":"Early Mortality among Immunocompetent Patients of Tuberculous Meningitis: A Prospective Study","volume":"101","author":"Jaipuriar RS","year":"2019","unstructured":"Jaipuriar RS et al (2019) Early Mortality among Immunocompetent Patients of Tuberculous Meningitis: A Prospective Study. Am J Trop Med Hyg 101:357\u2013361","journal-title":"Am J Trop Med Hyg"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55415","article-title":"Host sirtuin 2 as an immunotherapeutic target against tuberculosis","volume":"9","author":"Bhaskar A","year":"2020","unstructured":"Bhaskar A et al (2020) Host sirtuin 2 as an immunotherapeutic target against tuberculosis. Elife 9","journal-title":"Elife"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e1002262","DOI":"10.1371\/journal.ppat.1002262","article-title":"Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs","volume":"7","author":"Subbian S","year":"2011","unstructured":"Subbian S et al (2011) Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 7:e1002262","journal-title":"PLoS Pathog"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites GE","year":"2004","unstructured":"Thwaites GE et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351:1741\u20131751","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1038\/s41467-025-58190-x","article-title":"Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis","volume":"16","author":"Singh M","year":"2025","unstructured":"Singh M et al (2025) Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun 16:3003","journal-title":"Nat Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12974-016-0631-6","article-title":"Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat","volume":"13","author":"Wang JY","year":"2016","unstructured":"Wang JY et al (2016) Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. J Neuroinflammation 13:168","journal-title":"J Neuroinflammation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/jrf.0.0440109","article-title":"Permeability of the syrian hamster placenta to manganous ions during early embryogenesis","volume":"44","author":"Hanlon DP","year":"1975","unstructured":"Hanlon DP, Gale TF, Ferm VH (1975) Permeability of the syrian hamster placenta to manganous ions during early embryogenesis. J Reprod Fertil 44:109\u2013112","journal-title":"J Reprod Fertil"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1741-7015-11-74","article-title":"Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness","volume":"11","author":"Berk M","year":"2013","unstructured":"Berk M et al (2013) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74","journal-title":"BMC Med"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052782","article-title":"The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice","volume":"22","author":"Michael J","year":"2021","unstructured":"Michael J et al (2021) The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice. Int J Mol Sci 22","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.nicl.2014.09.002","article-title":"Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review","volume":"6","author":"Heye AK","year":"2014","unstructured":"Heye AK, Culling RD, Hernandez Mdel V, Thrippleton C, M.J., Wardlaw JM (2014) Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin 6:262\u2013274","journal-title":"Neuroimage Clin"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e36463","DOI":"10.1097\/MD.0000000000036463","article-title":"Evaluation of cerebrospinal fluid levels for ALOX5, S100B, DEFA1, and GFAP in infectious meningitis","volume":"102","author":"Baran AI","year":"2023","unstructured":"Baran AI et al (2023) Evaluation of cerebrospinal fluid levels for ALOX5, S100B, DEFA1, and GFAP in infectious meningitis. Med (Baltim) 102:e36463","journal-title":"Med (Baltim)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/cid\/cix540","article-title":"Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis","volume":"65","author":"Rohlwink UK","year":"2017","unstructured":"Rohlwink UK et al (2017) Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis. Clin Infect Dis 65:1298\u20131307","journal-title":"Clin Infect Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2014.12.027","article-title":"Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis","volume":"45","author":"Te Brake L","year":"2015","unstructured":"Te Brake L et al (2015) Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 45:496\u2013503","journal-title":"Int J Antimicrob Agents"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis","volume":"374","author":"Heemskerk AD","year":"2016","unstructured":"Heemskerk AD et al (2016) Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 374:124\u2013134","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim J","year":"2020","unstructured":"Kim J, Koo BK, Knoblich JA (2020) Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 21:571\u2013584","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1242\/dev.166074","article-title":"Brain organoids: advances, applications and challenges","volume":"146","author":"Qian X","year":"2019","unstructured":"Qian X, Song H, Ming GL (2019) Brain organoids: advances, applications and challenges. Development 146","journal-title":"Development"},{"key":"ref45","unstructured":"Catalizing the Development and Use of Novel Alternative Methods (2023) Advisory Committee to the Director, National Institutes of Health"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects","volume":"53","author":"Bolton AE","year":"2004","unstructured":"Bolton AE et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102\u2013106","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref47","article-title":"Elimination of senescent cells with senolytic host-directed therapy reduces tuberculosis progression in mice","author":"Shee S","year":"2025","unstructured":"Shee S et al (2025) Elimination of senescent cells with senolytic host-directed therapy reduces tuberculosis progression in mice. bioRxiv","journal-title":"bioRxiv"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis RS","year":"2021","unstructured":"Wallis RS et al (2021) Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med 9:897\u2013908","journal-title":"Lancet Respir Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1038\/s41467-023-43937-1","article-title":"Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide","volume":"14","author":"Krug S","year":"2023","unstructured":"Krug S et al (2023) Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. Nat Commun 14:8161","journal-title":"Nat Commun"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/088307380401900402","article-title":"Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study","volume":"19","author":"Schoeman JF","year":"2004","unstructured":"Schoeman JF et al (2004) Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 19:250\u2013257","journal-title":"J Child Neurol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"100871","DOI":"10.1016\/j.eclinm.2021.100871","article-title":"Aspirin in tuberculous meningitis","volume":"35","author":"Davis AG","year":"2021","unstructured":"Davis AG, Wilkinson RJ (2021) Aspirin in tuberculous meningitis. EClinicalMedicine 35:100871","journal-title":"EClinicalMedicine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.1460-2075.1985.tb03725.x","article-title":"A Raman spectroscopic investigation of the lipid state in acetylcholine receptor-rich membranes from Torpedo marmorata","volume":"4","author":"Aslanian D","year":"1985","unstructured":"Aslanian D, Negrerie M (1985) A Raman spectroscopic investigation of the lipid state in acetylcholine receptor-rich membranes from Torpedo marmorata. EMBO J 4:965\u2013969","journal-title":"EMBO J"},{"key":"ref53","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults","volume":"7","author":"Mai NTH","year":"2018","unstructured":"Mai NTH et al (2018) A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife 7","journal-title":"Elife"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"ofaa604","DOI":"10.1093\/ofid\/ofaa604","article-title":"Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions","volume":"8","author":"Marais BJ","year":"2021","unstructured":"Marais BJ et al (2021) Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infect Dis 8:ofaa604","journal-title":"Open Forum Infect Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/sti.2005.017863","article-title":"Montelukast in the treatment of HIV associated immune reconstitution disease","volume":"82","author":"Hardwick C","year":"2006","unstructured":"Hardwick C et al (2006) Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 82:513\u2013514","journal-title":"Sex Transm Infect"},{"key":"ref56","article-title":"Pharmacokinetics of Dexamethasone in Tuberculous Meningitis","author":"Calderin JM","year":"2025","unstructured":"Calderin JM et al (2025) Pharmacokinetics of Dexamethasone in Tuberculous Meningitis. Clin Infect Dis","journal-title":"Clin Infect Dis"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2125.2009.03478.x","article-title":"Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects","volume":"68","author":"Nassr N","year":"2009","unstructured":"Nassr N et al (2009) Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 68:580\u2013587","journal-title":"Br J Clin Pharmacol"},{"key":"ref58","article-title":"Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis","author":"Chen X","year":"2026","unstructured":"Chen X et al (2026) Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. J Infect Dis","journal-title":"J Infect Dis"},{"key":"ref59","author":"Fang H","year":"2025","unstructured":"Fang H et al (2025), APOE genotype confers context-dependent neurovascular vulnerability in immune-vascularized human forebrain organoids. bioRxiv"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8694483\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8694483\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:05:55Z","timestamp":1784703955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8694483\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":59,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8694483\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41467-026-75202-6","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,3,8]]},"subtype":"preprint"}}